Novo Nordisk's Wegovy, Fiasp, Ryzodeg Injectables Stolen During Transit, DCGI Issues Alert

Published On 2025-08-23 09:30 GMT   |   Update On 2025-08-23 09:30 GMT
Advertisement

New Delhi: The Drugs Controller General of India (DCGI) has issued an alert for doctors and healthcare professionals to carefully prescribe and educate the patients for reporting of any adverse drug reactions (ADRs) after pharmaceutical major Novo Nordisk reported the theft of multiple products of its critical rDNA-origin injectable medicines, including the popular weight loss drug semaglutide and the diabetes treatment insulin aspart, during transit from its Bhiwandi Hub to milk route (Nagpur, Raipur, Cuttack, and Kolkata).

The stolen products include widely used diabetes and obesity treatments such as Ryzodeg FlexTouch (insulin degludec/insulin aspart), Fiasp (insulin aspart) Penfill and FlexTouch, and Wegovy (semaglutide injections).

Novo Nordisk has raised a concern, citing, "The products under consideration are rDNA-origin injectables, which are required to be stored at 2-8°C. The quality of the products may be compromised if the products are not handled in proper storage conditions since the formulations are supposed to be maintained at 2°C to 8°C, failing which would impact the quality of the product and in turn impact the safety of the patients.

Advertisement

The list of products is as follows:

S. No.

Name of the product

Batch No.

Insulin degludec/insulin aspart (r-DNA origin solution for injection) (Ryzodeg FlexTouch)

RT6GY96

Insulin aspart (r-DNA Origin), solution for injection (Fiasp Penfill)

RR726A8

Insulin aspart (r-DNA Origin), solution for injection (Fiasp FlexTouch)

RP5P640

Semaglutide Injection 0.5 mg (r-DNA Origin), solution for injection (Wegovy FlexTouch)

RP S233

Semaglutide Injection 0.25mg (r-DNA Origin), solution for injection (Wegovy FlexTouch)

RP S232

Semaglutide Injection 1 mg (r-DNA Origin), solution for injection (wegovy FlexTouch)

RP5S210

The matter is currently under investigation by the police.

However, based on the above, the following advisory is provided:

Doctors and Healthcare professionals

• Carefully prescribe and educate the patients for reporting of any ADRs.

Patients and consumers

• To be careful and procure the above products from authorized sources only and with proper invoice.

Regulatory authorities (All state/UT Drugs Controllers and Zonal/Sub-Zonal offices of CDSCO)

Instruct your officers to keep a strict vigil on the movement of the said products in the market and initiate necessary action under the provisions of Drugs & Cosmetics Act, 1940 and Rules made thereunder

Commenting on the matter, the pharmaceutical major Novo Nordisk, in a statement as quoted in the ET, read, "We are aware of the unfortunate theft of a minor quantity of Novo Nordisk medications during transportation by our distribution partners. The incident has been reported to the relevant authorities, and we are fully cooperating with the ongoing investigation."
"We remain committed to delivering safe and effective treatments for those who rely on us," the company mentioned.

Additionally, they stated that patient safety is and will remain their "top priority."

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News